Strike Pharma is a Swedish biotech company with a proprietary technology for targeted LNP delivery, enabling in vivo CAR therapies for autoimmune disease and cancer. Specifically our technology provides a solution for CMC challenges related to manufacturing and long-term storage, as well as efficacy and immunogenicity, based on an affinity conjugation technology that allows post-storage attachment of the targeting antibody to the LNP.
Learn more about our Technology, Pipeline and Disease indications, and see our Publications and posters.